In utero exposure to endocrine disrupting chemicals (EDCs) may affect adult health. Di-(2-ethylhexyl) phthalate (DEHP) is an EDC widely used in the production of polyvinyl chloride products and an ubiquitous environmental contaminant. We used a rat model system to show that fetal exposure to DEHP decreased levels of major steroid hormones in adulthood and that environmentally-relevant levels of DEHP affected both gene expression and epigenomic loci that were affected by exposure to high levels. In the adrenal gland, we reported that the peroxisome proliferator-activated receptor (PPAR) and cholesterol biosynthesis pathways were sensitive targets of DEHP. We hypothesized that low levels of DEHP exposure insult the endocrine system (a "first hit") and increase its susceptibility to later exposure ("second hit") and subsequent disease. Here, we demonstrate that a second hit in the adult offspring exposed in utero to low levels of DEHP affected serum aldosterone levels. To unveil the first hit influence of early DEHP exposure, we treated in utero DEHP-exposed adult offspring with stressors that targeted the PPAR or cholesterol biosynthesis pathways. Treatment with the PPAR-gamma antagonist T0070907 reduced serum aldosterone compared to animals not exposed to DEHP in utero. Analysis of gene expression in animals that were subjected to both early and late exposure revealed deregulation of genes for the potassium channel Kcnk5 and the retinoid-X receptors (RXR) Rxra and Rxrb, indicating that these entities are linked to endocrine disruption. We propose that early exposure to environmental doses of DEHP predisposes the animal for disease later in life. (Endocrinology 158: 304-318, 2017) E ndocrine-disrupting chemicals (EDCs) are chemicals that interfere with endogenous endocrine signaling (1). Manmade EDCs are present in a wide variety of commercial products and are ubiquitous environmental contaminants. This has led to widespread exposure of humans to EDCs, as is apparent from studies of their presence in body fluids (2, 3). Given this background, the role of these chemicals in disease is clearly relevant to public health. Exposure to EDCs has been correlated with obesity, diabetes, decreased reproduction, cancer, and other developmental diseases (4). The mechanisms by which EDCs promote disease are complex and likely epigenetic because physiological changes are not immediately evident even when exposures are acute and exceed those of the general population. Particularly troubling is the possibility that exposure to EDCs during fetal development or childhood may influence disease later in life, a concern recently articulated by the Endocrine Society (4). Because EDCs interfere with hormonal signals, their disruptive effects may be greatest during this critical developmental period. The hypothesis underlying this concern is known as the fetal origins of disease hypothesis (5). The possibility also arises that any health risks associated with early Abbreviations: ANOVA, analysis of variance; ATII, angiotensin II; BW, body weight; DEHP, di-(2-ethylhexyl) phthalate; EDC, endocrine-disrupting chemical; FDR, false discovery rate; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; MAPK, mitogen-activated protein kinase; PCR, polymerase chain reaction; PND, postnatal day; PPAR, peroxisome proliferator-activated receptor; qPCR, quantitative polymerase chain reaction; RXR, retinoid X receptor; SEM, standard error of the mean.
exposure may not be mitigated by removing the chemical from the environment.
Di-(2-ethylhexyl) phthalate (DEHP) is an EDC used in the manufacturing of polyvinyl chloride products and cosmetics and as an excipient in some medications (6) . It is not permanently bound to the plastic polymer and is eventually released into the environment, where it may enter the food chain. This is a major source of direct exposure (7) . Other sources of direct phthalate exposure are dermal contact and inhalation of contaminated air particles. Indirect exposure during early development may occur when DEHP and its metabolites are transferred from the mother to the fetus and newborn through the fetalplacental unit and breast milk, respectively (8, 9) . Human exposure normally ranges from 1.7 to 52.1 mg/kg body weight (BW) per day (10-13) but can be as high as 10 mg/kg BW per day during medical procedures such as blood transfusions, use of parenteral nutrition, and extracorporeal perfusion (14) (15) (16) (17) (18) . Newborns and infants are exposed to higher levels of phthalates because of their increased food intake and metabolism. Direct exposure starts soon after birth when the infant encounters DEHP in the environment (19) , in breastfeeding, and in baby formula (20) . High levels of DEHP and its metabolites in urine have been positively correlated with cryptorchidism (21) , decreased anogenital distance (22) , and decreased testosterone levels in an adult population (23) .
Animal models have been central in research designed to elucidate the mechanisms by which EDCs affect disease processes, in both the short and the long term. Such models have permitted researchers to identify the developmental periods of greatest sensitivity to EDCs ("windows of exposure") and dissect complex epigenetic mechanisms (24) . In previous studies with a rat model system, we exposed pregnant dams to DEHP, beginning on gestational day 14, shortly after the fetal adrenal glands and testes had separated from their adrenogonadal precursor, and continued until the dams gave birth (25, 26) . This in utero exposure affected the adult endocrine physiology, resulting in 50% reductions in serum testosterone and aldosterone in adult male offspring (27) (28) (29) . This decrease in aldosterone persisted in the elderly rat and correlated with a lower blood pressure level (30) , suggesting adrenal function was affected in the long term. In the female offspring, a similar effect was seen, with estradiol and aldosterone levels being reduced following in utero exposure to DEHP (31) .
This research led us to attempt to elucidate the mechanism of the long-term effects of DEHP (24) on adrenal function. Our findings can be summarized as follows: The peroxisome proliferator-activated receptor (PPAR) and mitogen-activated protein kinase (MAPK) signaling pathways were affected in the long term by DEHP, as shown by global gene expression analysis in whole adrenal glands (32) . We identified that the lipid and lipoprotein metabolism, angiotensin II (ATII), and potassium-stimulation pathways are affected by DEHP in adults but not in adolescent offspring. We also noted that immune system-related genes are affected by DEHP exposure. Of particular interest, although endocrine disruption in male offspring was detected at 100 mg DEHP/kg BW per day, we identified changes in Ppara mRNA expression at a much lower dose, 1 mg/kg BW per day, similar to those detected in the environment. It may be, then, that the levels of DEHP in the human environment are sufficient to affect gene expression. In our study, DEHP was cleared from the offspring soon after birth, and they were not exposed to DEHP again. This led us to speculate that adult gene-expression changes in response to DEHP are mediated by an epigenetic mechanism. We used a genome-wide screening technique to analyze this question and identified several hot spots of DNA methylation in the adult adrenal gland (33) . Moreover, similar to the mRNA changes in Ppara observed at low levels of DEHP, we identified several CpGs that were affected at dosages as low as 1 mg DEHP/kg BW per day. We suggest that low levels of DEHP exposure were sufficient to affect the epigenome and gene expression, but the adrenal gland compensated for these changes to maintain endocrine homeostasis.
We propose that initial exposure to low doses of DEHP during a fetal window of development (a "first hit") may later affect the adrenal gland to increase its vulnerability to a second exposure (a "second hit") that compromises adrenal function. Here, we identify gene changes in key adrenal pathways that we defined as the first hit of DEHP. We used various compounds that target the PPAR and cholesterol biosynthesis pathways as secondary stressors in adults that were exposed in utero to DEHP. We show that gene changes following prenatal exposure to DEHP predispose the adrenal steroid physiology for a second hit in the adult.
Materials and Methods

Animal care and DEHP treatment
Timed pregnant Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA). Rats had access to chow (Harlan Laboratories, Indianapolis, IN; Catalog No. T.201815) and water ad libitum and were maintained in a 12-hour light, 12-hour dark cycle with lights on at 7:00 AM. Pregnant dams were gavaged daily with either corn oil (the vehicle) or DEHP at one of these doses: 0.5, 1, 50, 100, or 300 mg DEHP/kg BW per day (Sigma-Aldrich Corp., St. Louis, MO), from gestational day 14 to parturition (postnatal day [PND] 0). We refer to in utero exposure of 0.5 and 1 mg DEHP/kg BW per day as low-level exposure and 100 and 300 mg DEHP/kg BW per day as high-level exposure. Male offspring were euthanized with CO 2 on the morning of PND60. Blood was collected by percutaneous cardiac puncture, and adrenal glands were snap frozen. The animals were handled according to the protocols approved by the McGill University Animal Care and Use Committees.
Stressor treatment
Adult male offspring of pregnant dams were injected intraperitoneally with vehicle or a stressor compound from PND54 to PND59. The stressor compounds were atorvastatin (0.5 mg/kg BW per day), GW0742 (0.5 mg/kg BW per day), T0070907 (1 mg/kg BW per day), pioglitazone (1 mg/kg BW per day), GW0742 + atorvastatin (0.5 mg/kg BW per day each), T0070907 + atorvastatin (1 and 0.5 mg/kg BW per day, respectively), and pioglitazone + atorvastatin (1 and 0.5 mg/kg BW per day, respectively) (Tocris Bioscience, Bristol, United Kingdom). The compounds were chosen because they directly target the PPAR and cholesterol biosynthesis pathways previously found to be affected by in utero exposure to DEHP. Compounds were dissolved in phosphate-buffered saline containing 10% dimethyl sulfoxide and 10% Tween 80. The experiments were carried out in 3 rounds as follows: round 1 consisted of GW0742 (n = 5); round 2 consisted of GW0742 + atorvastatin (n = 5) and T0070907 (n = 5); and round 3 consisted of atorvastatin (n = 7), T0070907 + atorvastatin (n = 7), pioglitazone (n = 6), and pioglitazone + atorvastatin (n = 4).
RNA extraction and global gene expression analysis
Adrenal glands were collected from the offspring on PND60, and the adrenal capsule containing the zona glomerulosa was isolated as previously described (34) . Total RNA was extracted using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany) that included a DNase step, according to the manufacturer's instructions. The quality and concentration of total RNA were assessed with the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) and the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). The mRNA was reverse transcribed, fluorescently tagged, and hybridized to a Rat Gene 2.0 ST Array (Affymetrix, Inc., Santa Clara, CA) at the Génome Québec Innovation Centre. Data analyses were performed by Dr. Jaroslav Novak (STADIM, Montreal, QC, Canada) as previously described (35) . Briefly, gene signals were processed and normalized using the Robust Multi-Array Average algorithm. Differential expression of genes compared with the vehicle was analyzed using a t test with the Benjamini-Hochberg correction for multiple testing complemented by the nonparametric consecutive sampling method. The genes selected in the 0.5 mg DEHP/kg BW per day group satisfied the following conditions: ratio of sample averages $1.3 with a BenjaminiHochberg false discovery rate (FDR) value #0.1. Genes excluded by the Benjamini-Hochberg correction but with a consecutive sampling coincidence number $10 of 16 pairwise comparisons were included for analysis. The upregulated genes selected in the 1 mg DEHP/kg BW per day treatment group satisfied the following condition: ratio of sample averages $1.3 with a less stringent Benjamini-Hochberg FDR value #0.15 due to a smaller sample size. The downregulated genes selected had a ratio of sample averages $1.3 with a BenjaminiHochberg FDR value #0.1. Genes excluded by the BenjaminiHochberg correction but with a consecutive sampling coincidence number $7 of 12 pairwise comparisons were included for analysis. After quality control analysis, 4 replicates (n = 4) comprised the vehicle group (control), and the group receiving 0.5 mg DEHP/kg BW per day and 3 replicates (n = 3) comprised the group receiving 1.0 mg DEHP/kg BW per day. Pathway analysis and gene clustering were performed using the DAVID (36) and Reactome (37) bioinformatics portals. Venn diagrams were prepared using FlexArray 1.6. Selected genes were compared with global gene expression data previously obtained from whole adrenal glands exposed in utero to 300 mg DEHP/kg BW per day (32) . Gene expression data of primary zona glomerulosa cells treated with 100 nM ATII or 16 mM potassium for 2 hours were retrieved from GEO DataSets with the accession number GSE8421 (38) .
Quantitative real-time PCR analysis
Reverse transcription of 800 ng total RNA was performed with the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. Quantitative polymerase chain reaction (qPCR) was performed on the LightCycler 480 System (Roche Diagnostics, Basel, Switzerland). The multiplex qPCR mix consisted of 10 mL TaqMan Gene Expression Master Mix (Thermo Fisher Scientific), 2 mL cDNA, 6 mL water, 1 mL FAM-labeled gene target TaqMan probe, and 1 mL VIC-labeled glyceraldehyde-3-phosphate dehydrogenase (Gapdh) for a final volume of 20 mL. Gapdh was validated and used as an endogenous reference gene. The comparative Ct method was used to calculate gene expression relative to the Gapdh reference gene. Supplemental Table 1 contains a list of the TaqMan probes used with the TaqMan gene expression master mix (Thermo Fisher Scientific).
Serum measurements
Serum aldosterone was measured with a monoclonal enzyme immunoassay kit (Cayman Chemical Co., Ann Arbor, MI; Catalog No. 10004377) according to the manufacturer's instructions. Testosterone was measured using radioimmunoassay as previously described (28) . The intra-assay coefficients of variation for the aldosterone and testosterone immunoassays were 5.5% and 8.2%, respectively. All samples were assayed in duplicate. Mean values of serum aldosterone ranged between 64.3 and 900.8 pg/mL and were above the 80% B/B 0 limit. Mean values of serum testosterone ranged between 0.25 and 2.67 ng/mL and were above the 80% B/B 0 limit. Serum was shipped to Diagnostic Laboratory Services at McGill Comparative Medicine and Animal Resources Centre for measurement of serum electrolyte, cholesterol, high-density lipoprotein, and triglyceride levels.
Statistical analyses
GraphPad Prism program (GraphPad Software, Inc., La Jolla, CA) was used to calculate the mean 6 (standard error of the mean [SEM]) of the data. Statistical analyses of data were performed by Student t test, one-way analysis of variance (ANOVA) followed by Dunnett post hoc tests or by 2-way ANOVA followed by Bonferroni post hoc tests. The experimental unit was the pregnant dam. Three to 4 male offspring, each from different mothers, were examined independently for global gene expression analysis. Five to 6 male offspring, each from different mothers, were examined independently for qPCR analysis of DEHP-exposed zona glomerulosa. Five to 8 male offspring, each from different mothers, were examined independently for serum hormone levels and qPCR analysis in the second hit experiment. The number of animals used for each experiment are noted in each figure legend.
Results
In utero exposure to doses of DEHP similar to those in the environment affected the expression of genes in pathways that are associated with adult endocrine disruption at higher levels of DEHP exposure
From earlier work, we had ascertained that in utero exposure of male rats to high levels of DEHP altered aldosterone secretion and gene expression when the animals reached adulthood (29, 32) . We wished to determine if, and to what extent, low-level exposure (more similar to levels in the environment) affected these same genes. We assessed gene expression with global gene analysis in the zona glomerulosa from adult males that had been exposed in utero to 0.5 or 1 mg DEHP/kg BW per day and compared the results with our previous data of males exposed in utero to 300 mg DEHP/kg BW per day. The in utero exposure to DEHP deregulated 230 and 376 genes in the 0.5 and 1 mg DEHP/kg BW per day treatment groups, respectively, and 103 of these genes were altered in both groups [ Fig We wished to identify cellular functions and biological processes that were overrepresented and common to the 39 alternatively expressed genes. Using the DAVID Bioinformatics portal (36), we identified several genes that regulate transcription; these were Creb3l1, Crem, Giot1, Hhex, Iqub, Irak2, Nfil3, Nr4a1, Nr4a3, Ppp1r10, and Scx [ Fig. 1(B) ]. We also identified genes that regulate cholesterol metabolism; these were Hmgcr, Insig1, and Ldlr [ Fig. 1(B) ]. We also used the Reactome portal (37) to identify genes that are related to the immune system, specifically Dusp8, Irak2, Irs2, Nr4a1, Spsb1, and Tuba4a [ Fig. 1(B) ].
It was also of interest to determine if in utero exposure to DEHP affected the ATII or potassium pathways in the adrenal gland of the male rats. This was assessed by comparing gene expression in primary zona glomerulosa cells stimulated with 100 nM of ATII or 16 mM of potassium (38) with gene expression in adrenal glands of the male offspring exposed in utero to low doses of DEHP. Global expression arrays were prepared, and the results are presented in Fig. 1(C and  D) . Some of the genes that were differentially expressed in response to ATII or potassium were also differentially expressed in the DEHP-exposed adrenal glands of the male rats.
In utero exposure to low doses of DEHP deregulated zona glomerulosa pathways
In our previous transcriptomic work of whole adrenal glands from males exposed in utero to high doses of DEHP, we determined that the PPAR and MAPK signaling pathways are deregulated by DEHP, as well as cholesterol biosynthesis, lipid metabolism, and immune function in the pubertal and adult rat (32, 33) . Because this initial work was performed at high levels of DEHP, we wanted to determine if the genes that were deregulated at the lower doses are also involved in these pathways. Table 1 shows the results of the low-dose exposure. Several genes deregulated by the low-DEHP doses are associated with the innate and adaptive immune systems, and indeed, some of the genes deregulated at low doses are in the same pathways as those affected at the higher doses. These genes are involved in lipid and lipoprotein metabolism, PPARa-activated gene expression, MAPK family signaling, and transcription of nuclear receptors.
We concluded from previous results that in utero exposure of male rats to high levels of DEHP altered the expression of several transcription factors in the adrenal gland and these effects may be long-term. We observed here that low doses of DEHP also affected the gene expression of several transcription factors ( Table 2) . Some of these, for example Nr4a1, are critical for zona glomerulosa function (38) . We interpret these data as supporting the hypothesis that low levels of DEHP in utero, which are insufficient to affect aldosterone levels, deregulate some of the same genes that mediate adrenal endocrine disruption at higher DEHP doses.
We used qPCR to characterize the expression of selected genes that were deregulated by low and high doses of in utero DEHP exposure. Nr4a1, Nr4a3, Hmgcr, Insig1, Ldlr, and Kcnk5 had similar expression profiles (Fig. 2) . The data suggest that the dose-response curve for expression of each gene was nonmonotonic, with increased gene expression levels at 0.5, 1, and 300 mg DEHP/kg BW per day and with expression levels similar to those of the control at intermediate doses.
In utero exposure to DEHP predisposed the adrenal gland to endocrine disruption On the basis of the results presented, we concluded that genes with altered expression in response to both high and low doses of DEHP share common pathways. We next tested the hypothesis that the changes in gene expression at low doses of DEHP increased the susceptibility of the adrenal gland to further endocrine disruption. We reasoned that if the adrenal glands of animals exposed to DEHP in utero were more susceptible than those of control animals, stressing the gland in adulthood would impair adrenal function of the exposed
press.endocrine.org/journal/endoanimals more than the control. We used compounds that target either the PPAR or the cholesterol biosynthesis pathway as the agents of endocrine disruption, 2 of the pathways most dramatically affected by high levels of DEHP exposure. Male rats that had been exposed in utero to low levels of DEHP were injected with the PPARb agonist GW0742, the PPARg antagonist T0070907, or the PPARg agonist pioglitazone, either alone or in combination with atorvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor.
Atorvastatin was used to target the cholesterol biosynthesis pathway, a pathway previously shown to be deregulated by exposure to high levels of DEHP (29, 32) . We predicted that by targeting 2 separate pathways with the second hit, adrenal function might be sufficiently impaired. Serum aldosterone levels at PND60 showed that the PPARg antagonist T0070907 decreased aldosterone levels compared with the control [ Fig. 3 (A) ] but not when atorvastatin was supplied in conjunction with the antagonist. Testosterone levels were not significantly affected in DEHP-exposed males by any of the stressor combinations shown [ Fig. 3(B) ]. Because T0070907 was the only stressor for which a t test revealed a significant effect, this stressor was selected for further experiments. We used this compound to further study possible effects of the stressor in animals exposed to DEHP in utero. The reduced aldosterone levels observed in DEHP animals did not affect the circulating levels of serum electrolytes (data not shown).
Retinoid X receptors are involved in the decreased aldosterone levels after T0070907 stressor treatment
We wished to determine whether the PPARs and PPAR-related nuclear receptors were affected by the PPARg antagonist T0070907 and if these receptors are involved in reduced aldosterone secretion. Expression levels of Ppara and Pparg were not affected by the antagonist [ Fig. 4(A and B) ], whereas Ppard levels increased after treatment of the animals with T0070907. In utero exposure to 1 mg DEHP/kg BW per day alone resulted in a twofold increase in Ppard expression compared with the DEHP-free control [ Fig. 4(C) ]. We then measured gene expression of the retinoid X receptors (RXRs). The RXRs heterodimerize with PPARs and bind to peroxisome proliferator response elements in the DNA to regulate gene expression, making them key components of PPAR function and activity. Two-way ANOVA revealed an interaction between DEHP exposure and T0070907 treatment that resulted in a decrease in Rxra and Rxrb levels compared with the DEHP-free control [ Fig. 4(D and E) ]. There was no significant change in Rxrg levels [ Fig. 4(F) ] after treatment with the stressor.
The first hit of DEHP involved the Kcnk5 potassium channel
The characterization of the genes affected by lowdose exposure to DEHP and treatment with T0070907 was based on our previous transcriptomic work that identified genes that were sensitive to DEHP. To this end, we measured mRNA levels of the ATII receptors and 2 potassium channels, Kcnn2 and Kcnk5. Adrenal glands were collected from male offspring that had either not been exposed to DEHP in utero (1 control) or had been exposed in utero to 1 mg DEHP/kg BW per day. Additionally, 1 group was treated in adulthood with T0070907. The mRNA from the zona glomerulosa was isolated and analyzed with qPCR. Agtr1a and Agtr1b mRNA levels were lower in the glands from the animals treated with T0070907 [ Fig. 5(A and B) ] than in those from animals not treated with the stressor, and
Agtr1b mRNA levels were reduced by approximately 50% in the animals exposed to DEHP alone compared with the ones not treated in utero. There were no changes in Agtr2 levels [ Fig. 5(C) ] in any of these treatments. One-way ANOVA of the data was significant and was followed by Dunnett post hoc test. *P , 0.05; **P , 0.01; ***P , 0.001.
Kcnn2 and Kcnk5 encode potassium channels and were deregulated in whole adrenal glands at high levels of DEHP (32) . mRNA levels of Kcnn2 were less in the animals treated with T0070907 in adulthood [ Fig. 5(D) ] than in the control animals. Also, there was a trend for lower Kcnn2 mRNA levels in glands from animals treated in utero with DEHP alone than in glands from untreated animals [ Fig.  5(D) ]. Conversely, there was a twofold increase in Kcnk5 mRNA levels in animals exposed in utero to DEHP alone [ Fig. 5(E) ]; T0070907 treatment resulted in a decrease in Kcnk5 compared with DEHP-free males.
In utero exposure to 1 mg DEHP/kg BW per day and T0070907 stressor treatment did not affect expression of lipid and steroidogenic genes
We previously established that the hormone-sensitive lipase-mediated triglycerol hydrolysis pathway and cholesterol biosynthesis pathway are targets of DEHP in the Figure 3 . Circulating levels of (A) aldosterone and (B) testosterone in adult male rats treated in utero with DEHP and as adults with secondary stressors, with or without atorvastatin. Control animals were not exposed in utero to DEHP. The graphs show the results of 3 rounds of stressor experiments. Atorvastatin, n = 7; GW0742, n = 5; GW0742 + atorvastatin, n = 5; T0070907, n = 5; T0070907 + atorvastatin, n = 7; pioglitazone, n = 6; pioglitazone + atorvastatin, n = 4. Data represent mean 6 SEM; bars indicate significance by Student t test. *P , 0.05. doi: 10.1210/en.2016-1604 press.endocrine.org/journal/endowhole adrenal upon in utero exposure to $100 mg DEHP/kg BW per day (29, 32) . We measured mRNA levels of Lipe, Plin, Prkacb, Mgll, and Fabp4, genes associated with lipid metabolism, and Hmgcr and Scarb1, genes associated with cholesterol metabolism. mRNA levels of Lipe in the adrenal glands of male offspring treated with the stressor were lower than those of untreated controls [Supplemental Fig. 1(A) ]. There was no significant effect of DEHP exposure or stressor treatment on Plin, Prkacb, Mgll, or Fabp4 [Supplemental Fig. 1(B-E) ]. mRNA levels of Hmgcr in the adrenal glands of stressortreated male offspring were higher than levels in untreated animals [Supplemental Fig. 1(F) ]. There was no change in mRNA levels of Scarb1 in the adrenal glands [Supplemental Fig. 1(G) ]. Serum analysis revealed that circulating levels of cholesterol, triglycerides, and high-density lipoproteins were unaffected (data not shown).We explored expression of key steroidogenic enzymes and proteins as a potential explanation for the reduction in serum aldosterone. Star mRNA levels were increased in the T0070907 treatment group [Supplemental Fig. 2(A) ]. Exposure to 1 mg DEHP/kg BW per day alone resulted in a slight increase in Star expression compared with the DEHP-free control. There was no change in Tspo levels [Supplemental Fig. 2(B) ]. The level of Cyp11b2, the final enzyme in aldosterone biosynthesis, was unchanged by DEHP or the stressor treatment [Supplemental Fig. 2(C) ].
Discussion
We previously showed that fetal exposure to high levels of DEHP affected aldosterone blood serum levels in the adult rat, although levels at weaning were normal. We press.endocrine.org/journal/endohypothesized that expression of an adrenal gene(s) critical for adult aldosterone biosynthesis was affected in the long term (29) by in utero exposure. Because DEHP was rapidly cleared from the body and the offspring were not exposed again, we further hypothesized that the endocrine disruption of the adult adrenal gland was mediated by an epigenetic mechanism that had been altered in the fetus during development, although how this alteration came about is unknown. Global gene expression analysis from adrenal glands collected at weaning and in the young adult revealed that high levels of DEHP in utero affected the PPAR signaling and MAPK pathways at both time points (32) . However, it was only in the adult offspring that the cholesterol biosynthesis, angiotensin, and potassium pathways were deregulated by these high doses (32) . Deregulation of these particular pathways is strong evidence that DEHP hinders critical pathways in the aldosterone-producing cell: Cholesterol biosynthesis provides the building blocks for steroid hormones, and the other 2 pathways are the main regulators of zona glomerulosa function. Although DEHP has been mostly associated with antiandrogenic and reproductive effects (27, 39, 40) , these results led us to suggest that it also affects adrenal gland function.
To characterize the long-term epigenomic changes of in utero DEHP exposure, we used a genome-wide DNA methylation technique in the adult adrenal glands (33) . We previously showed that DEHP induced changes in CpG methylation levels throughout the adrenal epigenome and that some of the differential DNA methylation was clustered into hot spots in the genome. Interestingly, we observed changes in expression of Ppara and the DNA methylation of some CpG loci at low doses of DEHP that were not reflected in alteration of adrenal function and aldosterone secretion in the adult. These data led us to hypothesize that exposure to low doses of DEHP acts to increase the susceptibility of the genome to further exposure. We refer to this as the "two-hit" hypothesis.
Although our previous experiments were carried out in whole adrenal glands, the present work was done with purified zona glomerulosa cells in the hope of enhancing the sensitivity and specificity of detection methods. We also used a low dose of DEHP (1 mg/kg BW per day), which corresponds to the human equivalent of 0.16 mg DEHP/kg BW per day. Although higher than the estimated environmental human exposure of 13.8 mg DEHP/ kg BW per day (12) , it is within the range of medical (41, 42) and occupational (43, 44) exposures in adults (0.005 to 8.5 mg and 0.143 to 2 mg DEHP/kg BW per day, respectively).
Our first venture in this study was to characterize the global gene expression in the adult zona glomerulosa caused by fetal exposure to 0.5 and 1 mg DEHP/kg BW per day. There were 103 genes differentially expressed relative to the control and present in both treatments. We concluded that DEHP affected gene expression in the zona glomerulosa at doses 2 orders of magnitude lower than those required for endocrine disruption.
To compare the effects of low and high exposures to DEHP, we sorted the gene changes into the pathways we previously identified as deregulated by high exposure to DEHP using the Reactome bioinformatics portal. The data showed that genes in many of the pathways associated with endocrine disruption at high doses were deregulated at the lower doses of exposure. Genes in lipid-related pathways, which include cholesterol biosynthesis, the PPAR and MAPK pathways, and the nuclear receptor transcription pathway, were affected. Of interest, pathways related to immune function that include genes involved in the innate and adaptive immune system and in cytokine signaling were particularly affected by low doses of DEHP. These data are in agreement with our previous epigenetic study, which showed 2 hot spots of DNA methylation and gene deregulation following DEHP exposure in chr20p12 (33) , which houses the genes controlling the immune response (45) . Moreover, we and others have reported that DEHP also affects the immune system in adipose tissue (46) and testes (47) and may be caused by a variety of EDCs (48) . Together, the immune-related changes suggest that the immune response is also a target of DEHP and that the distinct effect of DEHP on chr20p12 may be mediating other diseases associated with DEHP exposure, such as asthma (49) , atopic disorders (50, 51) , and macrophage dysfunction (52, 53) . The data also showed that genes critical to the core zona glomerulosa function were targeted by DEHP. Hmgcr, the enzyme involved in the ratelimiting step in cholesterol biosynthesis, was upregulated at both 0.5 and 1 mg DEHP/kg BW per day. This suggested that cholesterol biosynthesis, an important pathway in providing precursors for aldosterone biosynthesis (54, 55) , is one of the most sensitive targets of DEHP. Moreover, Nr4a1, a master regulator of zona glomerulosa function (38) , was also affected in a manner similar to Hmgcr. Whether Nr4a1 and Hmgcr were upregulated to counter a drop in aldosterone biosynthesis or whether these genes were directly targeted by DEHP remains to be determined. The gene analysis also showed that Nr5a1 and Nr0b1, genes that are critical for adrenal development and steroid function (24) and, when mutated, can lead to adrenal insufficiency (56) , were also affected by DEHP. These genes, along with Nr4a1, are vital for adrenal gland zonation (57, 58) . On the basis of these data, we concluded that low doses of DEHP during fetal development alter genes critical for adrenal function. Although the zona glomerulosa appears to be unable to overcome the disruption of high concentrations of DEHP, it can overcome endocrine disruption at low doses.
We used Venn diagrams to examine relationships between the genes affected by DEHP at low and high doses of exposure and those involved in aldosterone biosynthesis after ATII or potassium stimulation. We found 39 genes that were altered in both the low and the high DEHP exposures, most of which were upregulated. Pathway analysis showed that these genes are involved in transcription, cholesterol metabolism, and embryonic organ development. It is interesting to note that the potassium channel Kcnk5 is a common target of DEHP in all these situations. Kcnk5 expression was inversely correlated, in both dose and time, with the decreased aldosterone levels induced by DEHP (32) . Moreover, we expanded our analysis to include genes that were differentially expressed in the zona glomerulosa stimulated with potassium or ATII. The data indicated that low levels of DEHP also affected the expression of some of these genes. This was surprising because, under normal conditions, the genes identified are only upregulated during acute stimulation. It may be, then, that DEHP alters the pathways that directly control aldosterone biosynthesis. We interpret these data, in total, to mean that low doses of DEHP targeted pathways that are critical and specific to zona glomerulosa function. We hypothesized that some of these genes are part of a compensatory mechanism to maintain aldosterone homeostasis and that a second stimulus directed at these pathways will unveil the epigenetic weakness established during fetal exposure to DEHP.
We quantified gene expression changes across the range of DEHP exposure. Despite the fact that only exposure to high doses of DEHP led to changes significant by the Dunnett test, we observed increases at low DEHP doses in the expression of the transcription factors Nr4a1 and Nr4a3, in genes related with cholesterol metabolism, including Hmgcr, Insig1, and Ldlr, and in the potassium channel Kcnk5, suggesting a nonmonotonic response in gene expression. The possibility that this pattern could be accounted for by variations in the reference gene used for the quantification analysis was ruled out by the expression patterns of other adrenal genes (data not shown). This distinct expression pattern, which was also observed for genes associated with the EDC phenotype, suggests that a common upstream element may be partly mediating the response to DEHP. At present, this upstream element is unknown, but we do not rule out that this nonmonotonic pattern of expression originated in the epigenomic regions that we previously identified (33) . Interestingly, our previous genome-wide DNA methylation analysis showed that none of the differentially methylated CpG loci were within or near genes affected by DEHP. Instead, most of the CpG changes occurred in CpG islands, shore, and shelf regions, which are associated with control of gene expression. Moreover, in some cases, the CpG clusters correlated with regional changes in gene expression. This latter point suggested to us that these areas contain regulatory elements that can affect the expression of a cluster of genes and that the effects on gene expression were likely a result of complex epigenetic interactions rather than direct effects between DNA methylation and gene expression.
The next experiment was designed to test the hypothesis that in utero exposure to DEHP compromises the adrenal gland, resulting in increased susceptibility to stress in the adult. From previous work, we knew that the PPAR pathway, a mediator of metabolism and immunity, is sensitive to DEHP so that compounds that affect PPAR nuclear receptors are likely candidates for stressors. The involvement of the PPAR pathway in aldosterone biosynthesis was previously shown in vitro in the H295R and HAC15 cell lines (59, 60) and in vivo, when a 7-day treatment with rosiglitazone, a PPARg agonist, reduced serum aldosterone levels in Sprague-Dawley rats (61) . We also considered compounds that affect the rate-limiting step of cholesterol biosynthesis. This information led us to select the PPARb agonist GW0742, the PPARg agonist pioglitazone, and the PPARg antagonist T0070907 as the stressors for this experiment. The stressors were used alone and in combination with atorvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. These stressors were injected into adult rats that had been exposed to low doses of DEHP in utero, and aldosterone levels were assessed and compared with those of animals that had no exposure to DEHP. The results showed that T0070907 treatment resulted in a significant reduction of serum aldosterone levels in DEHP-exposed offspring compared with levels in the oil control. This is a decrease of 2 orders of magnitude in the threshold for endocrine disruption.
In the last phase of the study, we searched for changes associated with the second hit, which was supplied with the challenge with T0070907. We examined genes known to be associated with the DEHP phenotype at high doses and assessed their expression in rats receiving low doses in utero and that were stressed as adults. We chose to examine PPAR nuclear receptors and the RXRs because these are known to form dimers with each other. Rxra and Rxrb expression was influenced by in utero exposure to a low dose of DEHP, a result that was unexpected and led us to wonder if the dimerizing partners of the PPARs may be important for endocrine disruption. In addition, gene expression of the ATII receptors and the members of the potassium pathways Kcnk5 and Kcnn2 were analyzed. Interestingly, Rxra, Rxrb, and Kcnk5 were downregulated with respect to the control, and it may be that a common transcription factor controlling their gene expression was absent. Kcnk5 (also known as TASK-2) encodes an acid-dependent potassium channel and has been shown to play a role in aldosterone production. Specifically, decreased expression of Kcnk5 has been determined to be a hallmark of aldosterone-producing adenomas (62, 63) . Because other genes involved in lipid metabolism and steroid biosynthesis were unaffected by the DEHP exposure, the data suggest that the RXRs and Kcnk5 mediated the decrease of aldosterone levels after the second hit.
In summary, the results presented here, in combination with results of our previous epigenetic and gene expression studies, suggest that in utero exposure to environmentally relevant doses of DEHP predisposes the adrenal gland to long-term endocrine disruption. Epigenetic changes caused by low doses of DEHP may result in permanent changes in the expression of genes and may be associated with other disease states.
